Now showing items 1-3 of 3

    • Developing drugs for developing countries. 

      Ridley, DB; Grabowski, HG; Moe, JL (Health Aff (Millwood), 2006-03)
      Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatmennts ...
    • Entry and competition in generic biologics 

      Grabowski, HG; Ridley, DB; Schulman, KA (Managerial and Decision Economics, 2007-06-01)
      Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In ...
    • Spending on postapproval drug safety. 

      Ridley, DB; Kramer, JM; Tilson, HH; Grabowski, HG; Schulman, KA (Health Aff (Millwood), 2006-03)
      Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regardding ...